Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06076850
Other study ID # JKEUPM-2023-073
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date July 1, 2023
Est. completion date June 30, 2025

Study information

Verified date October 2023
Source Hospital Pengajar Universiti Putra Malaysia
Contact Vincent Khor, ChM(Urol)
Phone +603-9769 9220
Email khorweisheng@upm.edu.my
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Radical prostatectomy (RP) is one of the curative treatment modalities for localized or locally advanced prostate cancer. Urinary incontinence and erectile dysfunction (ED) are two most common complications after RP. Despite the advancement of prostate cancer treatment, ED post-RP remains a significant morbidity especially for patients who are sexually active pre-operatively. To improve the sexual function post-surgery, numerous strategies have been described including preservation of neurovascular bundles intra-operatively, post-operative physiotherapy, on-demand phosphodiesterase 5-inhibitors (PDE5i), regular PDE5i, intra-carvenosal injection or vacuum suction device. Low-intensity extracorporeal shockwave therapy (LiESWT) is an emerging treatment modality of ED with promising result, and it is a well-established treatment of ED in patients with diabetes mellitus or vasculopathy. Most of the pre-clinical studies were done on post-RP ED rat models with bilateral cavernous nerve crush injury. LiESWT was observed to improve nerve-impaired ED significantly compared to sham procedures. There are currently one pilot study and one randomized controlled trial (RCT) published in the literature on this field. However, the published RCT was an open label study with no sham-controlled arm which could contribute to reporting bias and the treatment intensity might not be adequate. In our proposed study, we make a hypothesis that LiESWT and very early PDE5i can improve erectile function in patients after nerve-sparing radical prostatectomy.


Description:

Urinary incontinence and erectile dysfunction (ED) are two most common complications after RP. Despite the advancement of prostate cancer treatment, erectile dysfunction post-prostatectomy remains as a significant morbidity especially for patients who are sexually active pre-operatively. PDE5i such as Tadalafil, Sildenafil remains the main form of penile rehabilitation with limited success. Non-invasive treatment such as Li-ESWT has proven to be a good treatment option mainly for vasculogenic ED. This study aims to investigate the effect of Li-ESWT treatment on post-prostatectomy ED, along with regular PDE5i. Our hypothesis is that Low intensity extracorporeal shockwave therapy and very early PDE5i can improve erectile function in patients after nerve-sparing post-radical prostatectomy. Eligible patients will be randomized to intervention arm (LiESWT treatment for 6 weeks + Tadalafil 5mg daily for 12 months) or controlled arm (sham therapy for 6 weeks + Tadalafil 5mg daily for 12 months). The device used in this study is Dornier Aries 2, with treatment protocol as described. The vacuum pump is an option for penile rehabilitation protocol at our institution due to its expensive cost. Penile vacuum pumps are allowed for voluntary use by all participants in both groups. A sub-group analysis will be conducted at the conclusion of the study. Sexual outcomes will be assessed using IIEF (International Index of Erectile Function), EHS (Erectile Hardness Score) and Erectile Dysfunction Inventory of Treatment Satisfaction Score (EDITS) questionnaires at 1,3,6 and 12 months after completion of therapy.


Recruitment information / eligibility

Status Recruiting
Enrollment 70
Est. completion date June 30, 2025
Est. primary completion date June 30, 2025
Accepts healthy volunteers No
Gender Male
Age group 40 Years to 75 Years
Eligibility Inclusion Criteria: - Patients who underwent radical prostatectomy (open, laparoscopic or robotic-assisted) with nerve-sparing (unilateral or bilateral). - Low / intermediate-risk prostate cancer - PSA < 20 ng/ml - Gleason score < 8 - Prostate cancer pathological stage </= T2b - Sexually active with IIEF-5 score 3 18, with or without use of erectogenic aid / PDE5i. Exclusion Criteria: - Tumour upstaging beyond T2b - Neurovascular bundle tissues bilaterally in the histopathological report. - Scheduled treatment with pelvic radiotherapy and / or androgen deprivation therapy post-RP. - Men with ED of neuropathological, endocrine or psychogenic origin. - Previous pelvic surgery or radiation therapy. - Patients with uncontrolled psychiatric conditions. - Patients with major post-operative complications that could impact safety or effectiveness of ESWT. - Patients with heart disease - unable to take PDE5i or prohibited from sexual activity. - Patients on anticoagulation / antiplatelets except aspirin up to 100mg daily. - Inflammation in the shockwave area or having penile pathology such as Peyronie's disease.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Low-Intensity Extracorporeal Shockwave Therapy (LiEWST) - Active
Treatment protocol: EFD 0.096 mJ/mm2 2 sessions / week; 5000 shocks / session 6 weeks treatment total: 12 sessions Li-ESWT to start after removal of indwelling catheter
Low-Intensity Extracorporeal Shockwave Therapy (LiEWST) - Sham
Treatment protocol: EFD 0 mJ/mm2 2 sessions / week; 5000 shocks / session 6 weeks treatment total: 12 sessions Li-ESWT to start after removal of indwelling catheter

Locations

Country Name City State
Malaysia Hospital Sultan Abdul Aziz Shah, Universiti Putra Malaysia (previously known as HPUPM) Serdang Selangor

Sponsors (1)

Lead Sponsor Collaborator
Hospital Pengajar Universiti Putra Malaysia

Country where clinical trial is conducted

Malaysia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Sexual Function Measurement of average change in IIEF-5 score from baseline (pre-RP) to specified time-points at 1,3,6 and 12 months after completion of treatment - 22-25: No erectile dysfunction 17-21: Mild erectile dysfunction 12-16: Mild to moderate erectile dysfunction 8-11: Moderate erectile dysfunction 5-7: Severe erectile dysfunction 5 being the worst outcome 12 months
Secondary Stretched Penile Length Clinical measurement of change in stretched flaccid penile length from baseline specified time-points at 1,3,6 and 12 months after completion of treatment. 12 months
Secondary Urinary Function Measurement of average change in EPIC questionnaire score from baseline (pre-RP) to specified time-points at 1,3,6 and 12 months after completion of treatment. 12 months
Secondary Safety and Adverse Events Number of Participants With Treatment-Related Adverse Events as Assessed by Common Terminology Criteria for Adverse Events (CTCAE) v5.0 12 months
See also
  Status Clinical Trial Phase
Completed NCT05735223 - A Prospective Study to Evaluate the Impact of Maximal Urethral Length Preservation Technique During Robotic Laparoscopic Prostatectomy on the Stretched Flaccid Penile Length and Continence N/A
Recruiting NCT05868668 - Efficacy of Low-intensity Shockwave vs Radial Wave for Treatment of Erectile Dysfunction and Pelvic Pain N/A
Completed NCT03241758 - Vascular Changes Of Patients Undergoing Laparoscopic Radical Prostatectomy N/A
Recruiting NCT05558007 - Safety and Efficacy Evaluation of BZ371A Topically Applied on Prostatectomized Patients Phase 2
Completed NCT05332340 - Safety, Tolerability and Pharmacokinetics (PK) Evaluation of BZ371A, Topically Administered Phase 1
Completed NCT04491773 - Study of Retinal and Choriocapillary Vascular Changes in Patients Undergoing Tadalafil 20mg for More Than 6 Months
Recruiting NCT05650866 - Safety and Tolerability of a Novel Implantable Device for the Treatment of Erectile Dysfunction N/A
Recruiting NCT03905057 - Early Shockwave Therapy for Post-RP ED N/A
Not yet recruiting NCT06126874 - Additional Effects of Aerobic and Resistance Exercises to Pelvic Floor Muscle Training After Radical Prostatectomy N/A
Completed NCT05772598 - Validating the 'Sexual Minorities and Prostate Cancer Scale' to Gold Standard Questionnaires
Recruiting NCT05244486 - Efficacy of RestoreX Penile Traction Therapy In Preserving Erectile Function Post-Prostatectomy N/A
Not yet recruiting NCT06458855 - Nerve Grafting Technique to Restore Erectile Function Post Radical Prostatectomy N/A
Completed NCT00335634 - Sexual Dysfunction and Adaptation in Couples Affected by Prostate Cancer Surgery N/A
Recruiting NCT03862599 - Low Intensity Shock-wave Therapy (Li-ESWT) in Penile Rehabilitation After Radical Prostatectomy N/A
Active, not recruiting NCT04434352 - Low Intensity Shockwave Therapy for Erectile Dysfunction N/A
Completed NCT04164355 - Study of Retinal and Choriocapillary Vascular Changes in Patients Undergoing Tadalafil 20mg
Not yet recruiting NCT05960149 - Use of Indocyanine Green in Robotic Prostate Surgeries Phase 4
Terminated NCT01996852 - Improving Erectile Function and Quality of Life After Prostate Cancer Treatment N/A
Terminated NCT01770340 - Nerve Grafting With an Allograft During Radical Prostatectomy - Extended Follow-up in a Prospective Randomized Trial Phase 4
Not yet recruiting NCT05578157 - MENDiP: Measurements of Overnight Penile Temperature to Evaluate Nocturnal Erection Detection in Patients With Absence of Erectile Functioning After Robot-assisted Radical Prostatectomy